Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Beat the odds: new device uses music to retrain stroke Patients' gait

NCT ID NCT06051539

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a device called MR-001 that uses rhythmic auditory stimulation (like music or beats) to help people who have had a stroke walk better. 234 chronic stroke patients with walking problems used the device at home for 12 weeks. The goal was to see if it improves walking endurance and how often people use it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MR-001 (a device that uses rhythmic auditory stimulation to improve walking)
What this could lead to
If successful, this could provide an effective home-based therapy to improve walking and reduce healthcare costs for chronic stroke survivors.
What could go wrong
The trial is completed but results are not yet widely published. The device may not work for everyone, and benefits may not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

234 people

The number who actually took part.

Started

Oct 2023

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Equal to or greater than 6 months post-stroke with gait impairment 2. Age \>/= 18 - 85 years of age, inclusive 3. Understand and speak English 4. Must be able to ambulate without assistance from another person. Note: assistive devices are allowed. If a participant uses an assistive device at the time of enrollment, the device must be used for all walking sessions. 5. Willing to travel to a Velocity location to complete in-person gait assessments 6. Able to walk at a speed greater than or equal to 0.4 m/s as derived as an average of speed per minute from the 6MWT. Note: if a participant intends to use an assistive device throughout the intervention period, the assistive device must be used during the gait assessment. 7. Must have claims data available and consent to sharing. Exclusion Criteria: 1. Hearing impairment with or without the use of hearing aids such that the participant cannot hear the rhythmic stimulation of the music 2. Pain that impairs walking ability 3. Unable to safely participate in walking sessions as determined by investigator 4. Requires more than one rest (seated or not) during the 6MWT 5. Significant comorbid medical or neurological conditions that could impact gait or prevent safe participation as determined by the Investigator. For example: condition that prevents participation in exercise, e.g., Parkinson's disease, cerebral palsy, multiple sclerosis, myasthenia gravis, muscular dystrophy, or spinal cord injury. Note: major surgery within the last 3 months is exclusionary. 6. People who are pregnant or become pregnant (due to expected gait pattern changes). 7. Lower limb prosthetic 8. More than 2 falls in the previous month 9. Non-reciprocal gait pattern. Note: Note: a non-reciprocal gait pattern is defined as a 3-point step pattern. Participants must have a 2-point step pattern to qualify. Asymmetry seen in gait is acceptable. 10. Treatment with a gait-based investigational intervention within the last 3 months. 11. Unable or unwilling to provide informed consent to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Curavit Clinical Research - DECENTRALIZED CLINICAL TRIAL

    Portland, Maine, 04101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.